
United States · Information technology & services startup
Bio-Optronics is a healthcare software company based in Rochester, New York, founded in 1985.
Funding reportedLast round: Venture (Round not Specified)
Follow Bio-Optronics and see its new rounds in your feed.Start following
Bio-Optronics is a healthcare software company based in Rochester, New York, founded in 1985.
The company specializes in workflow optimization solutions for clinical trial management, medical staff scheduling, and patient safety. In March 2021, Bio-Optronics was acquired by Advarra, enhancing its capabilities in the healthcare information technology sector. The company offers a suite of software products, including Clinical Conductor, a Clinical Trial Management System that improves regulatory compliance and operational efficiency; Momentum, a physician and staff scheduling tool that automates scheduling processes; and Biopoint, a patient identification and safety system that ensures patient safety through data synchronization. Bio-Optronics also provides CCTrialSuite, an integrated suite of eClinical solutions, along with dedicated support and custom IT solutions for workflow management. Bio-Optronics serves a diverse range of healthcare organizations, including leading hospital systems, clinical research sites, medical groups, government agencies, and long-term care facilities.
Funding, as reported
What they build
Known for
health carectmscomputer & network securitypatient-centric solutionspatient recruitmentsite enablement servicesresearch staffingresearch traininginformation technology & serviceshybrid visit modelsstaff schedulingdata securityenrollment managementbudget negotiationclinical researchindustry-leading protocol dataset
Built with from their website
Ivory SearchAdobe Marketo EngageWistiaGoogle Tag ManagerWordPress.orgAtlassianSpectraViewport MetaEWWW Image OptimizerYoast
UKGThe Events CalendarGlide.jsMimecastCloudflare Rocket LoaderHubspotNew Relic Insightswebpack
Add your raise, your deck and your story, and put Bio-Optronics in front of investors. Or tell us what we have wrong.